An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease

Trial Profile

An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Adalimumab (Primary) ; Azathioprine; Prednisone
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms CALM
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 May 2017 Results (n=244) assessing the benefit of "treat to target" versus standard clinical management (CM) of Crohn's disease, presented at the Digestive Disease Week 2017.
    • 04 May 2017 According to an AbbVie media release, data from this trial will be presented at Digestive Disease Week (DDW) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top